文献速递垂体与肾上腺疾病

原发性醛固酮增多症与原发性高血压患者心血管事件及靶器官损害的对比:系统综述与荟萃分析

Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-11-09

该系统综述与荟萃分析纳入31项观察性研究,比较3838例原发性醛固酮增多症患者与9284例原发性高血压患者。中位随访8.8年后,原发性醛固酮增多症患者卒中、冠心病、心房颤动、心力衰竭、糖尿病、代谢综合征及左心室肥厚的风险均升高,肾上腺腺瘤与双侧肾上腺增生两亚组间无差异。

要点

  • 原发性醛固酮增多症患者卒中风险高于原发性高血压患者(OR 2.58,95%CI 1.93-3.45)。
  • 原发性醛固酮增多症患者心房颤动风险升高(OR 3.52,95%CI 2.06-5.99)。
  • 肾上腺腺瘤与双侧肾上腺增生两亚组间上述风险无差异。

核心结论

  • 在疾病早期诊断原发性醛固酮增多症并早期启动特异性治疗很重要,因为患者较原发性高血压患者心血管风险增加。

研究设计与样本

  • 对前瞻性和回顾性观察性研究进行荟萃分析,检索MEDLINE和Cochrane Library截至2017年2月28日发表的文献,无起始日期限制。
  • 纳入31项研究,包括3838例原发性醛固酮增多症患者和9284例原发性高血压患者。
  • 比较原发性醛固酮增多症与原发性高血压患者,并比较肾上腺腺瘤与双侧肾上腺增生亚组。

主要发现

  • 从高血压诊断起中位8.8年(IQR 6.2-10.7)后,原发性醛固酮增多症患者较原发性高血压患者卒中风险升高(OR 2.58,95%CI 1.93-3.45)。
  • 原发性醛固酮增多症患者冠心病风险升高(OR 1.77,95%CI 1.10-2.83),心房颤动风险升高(OR 3.52,95%CI 2.06-5.99),心力衰竭风险升高(OR 2.05,95%CI 1.11-3.78)。
  • 肾上腺腺瘤和双侧肾上腺增生患者结果一致,两亚组间无差异。
  • 原发性醛固酮增多症患者糖尿病风险升高(OR 1.33,95%CI 1.01-1.74),代谢综合征风险升高(OR 1.53,95%CI 1.22-1.91),左心室肥厚风险升高(OR 2.29,95%CI 1.65-3.17)。

关键数值与推荐

  • 卒中OR 2.58(95%CI 1.93-3.45),冠心病OR 1.77(95%CI 1.10-2.83),心房颤动OR 3.52(95%CI 2.06-5.99),心力衰竭OR 2.05(95%CI 1.11-3.78),均为原发性醛固酮增多症 vs 原发性高血压。
  • 糖尿病OR 1.33(95%CI 1.01-1.74),代谢综合征OR 1.53(95%CI 1.22-1.91),左心室肥厚OR 2.29(95%CI 1.65-3.17),均为原发性醛固酮增多症 vs 原发性高血压。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is conflicting evidence, relying on heterogeneous studies, as to whether aldosterone excess is responsible for an increased risk of cardiovascular and cerebrovascular complications in patients with primary aldosteronism. We aimed to assess the association between primary aldosteronism and adverse cardiac and cerebrovascular events, target organ damage, diabetes, and metabolic syndrome, compared with the association of essential hypertension and these cardiovascular and end organ events, by integrating results of previous studies. METHODS: We did a meta-analysis of prospective and retrospective observational studies that compared patients with primary aldosteronism and essential hypertension, to analyse the association between primary aldosteronism and stroke, coronary artery disease (as co-primary endpoints), atrial fibrillation and heart failure, target organ damage, metabolic syndrome, and diabetes (as secondary endpoints). We searched MEDLINE and Cochrane Library for articles published up to Feb 28, 2017, with no start date restriction. Eligible studies compared patients with primary aldosteronism with patients with essential hypertension (as a control group) and reported on the clinical events or endpoints of interest. We also compared primary aldosteronism subtypes, aldosterone-producing adenoma, and bilateral adrenal hyperplasia. FINDINGS: We identified 31 studies including 3838 patients with primary aldosteronism and 9284 patients with essential hypertension. After a median of 8·8 years (IQR 6·2-10·7) from the diagnosis of hypertension, compared with patients with essential hypertension, patients with primary aldosteronism had an increased risk of stroke (odds ratio [OR] 2·58, 95% CI 1·93-3·45), coronary artery disease (1·77, 1·10-2·83), atrial fibrillation (3·52, 2·06-5·99), and heart failure (2·05, 1·11-3·78). These results were consistent for patients with aldosterone-producing adenoma and bilateral adrenal hyperplasia, with no difference between these subgroups. Similarly, primary aldosteronism increased the risk of diabetes (OR 1·33, 95% CI 1·01-1·74), metabolic syndrome (1·53, 1·22-1·91), and left ventricular hypertrophy (2·29, 1·65-3·17). INTERPRETATION: Diagnosing primary aldosteronism in the early stages of disease, with early initiation of specific treatment, is important because affected patients display an increased cardiovascular risk compared with patients with essential hypertension. FUNDING: None.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2017. PMID: 29129575. doi:10.1016/S2213-8587(17)30319-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。